Shelley Schmitz Remkes, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 125 Mallard St, Ste C, Saint Rose, LA 70087 Phone: 504-712-7858 Fax: 504-712-4799 |
William E. Miller Jr., R.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 125 Mallard St, Ste. C, Saint Rose, LA 70087 Phone: 800-225-5967 Fax: 909-799-4364 |
Richard Irvin Miller, LA 14443 Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 400 Riverwood Dr, Saint Rose, LA 70087 Phone: 504-236-3320 Fax: 504-467-2471 |
News Archive
Impulse Accelerated Technologies today announced that its CoDeveloper C-to-FPGA compiler has been used to develop and deploy a DNA biotechnology genome search algorithm on a new, modular FPGA acceleration platform created by Pico Computing, of Seattle, Washington. The Xilinx FPGA-accelerated bioinformatics algorithm, written in C, performs sequence analysis and pair-match scoring of DNA runs with lengths of 25 base pairs.
By employing optogenetics, a new field that uses genetically altered cells to respond to light, and a tandem unit cell (TCU) strategy, researchers at Stony Brook University have demonstrated a way to control cell excitation and contraction in cardiac muscle cells, the details of which are published in the early online edition of Circulation: Arrhythmia & Electrophysiology: "Stimulating Cardiac Muscle by Light: Cardiac Optogenetics by Cell Delivery."
The opioid crisis is one of the largest challenges facing today's healthcare professionals and the patients for whom they care.
Breast cancer patients are more likely to have joint pain from taking aromatase inhibitors if they have advanced stage cancer, according to a study presented at the American College of Rheumatology's annual meeting, held Nov. 7-11, in Atlanta. The study is one of the first to identify factors that increase the likelihood that a patient will suffer joint pain from AI therapy.
Researchers at National Jewish Health and the University of Colorado School of Medicine have used a new strategy to develop cancer vaccines that are remarkably effective in mice. In the February 16 issue of the Proceedings of the National Academy of Sciences, Kimberly Jordan, PhD, Jill Slansky, PhD, and John Kappler, PhD, report that 100 percent of the mice vaccinated with a peptide they developed remained alive and tumor-free for at least 60 days after inoculation with colon cancer cells.
› Verified 8 days ago